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Background: The out-of-hospital cardiac arrest represent the leading cause
of death worldwide. Several therapeutic elements such as early reperfusion
developed in recent years to reduce the high morbidity and mortality observed
in this situation. The objective of this study was to evaluate the influence of
emergency coronary angiography (CAG) and primary percutaneous coronary
intervention (PCI) on the outcome of patients survivors after out-of-hospital
cardiac arrest.
Methods: Between January 2012 and June 2013, a total of 54 consecutive
patients survivors of out-of-hospital cardiac arrest underwent systematic emer-
gency coronary angiography.
Results: Thirty five of the 54 patients had clinically significant coronary
disease on angiography, 23 of whom had coronary-artery occlusion (43 %).
Angioplasty was attempted in 20 patients and was technically successful in 18.
The in-hospital survival rate was 48 %. Multivariate logistic-regression anal-
ysis revealed that angioplasty was an independent predictor of survival
(95 percent confidence interval, 3.1 to 750.1; P =0.006).
Conclusions: Acute coronary-artery occlusion is frequent in survivors of
out-of-hospital cardiac arrest. Accurate diagnosis by immediate coronary
angiography can be followed in suitable candidates by coronary angioplasty,
which seems to improve survival.
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Cardiovascular diseases (CVDs) are a major cause of mortality (up to 40%
death). CVDs are highly inheritable, suggesting a major role of genetic fac-
tors. Identifying key genes remain difficult as individual CVD risks are often
linked to multiple undetermined genes and their interaction with environ-
mental parameters. Significant progress have been made recently with the
identification of nearly 120 genomic regions including variants associated
with CVD accrued risk. These studies involve genome-wide associated data
and are most helpful but cannot allow to accurately identify gene and the spe-
cific impact of each genetic variant in different physiological and metabolic
events associated with CVDs. Starting from the Ludwigshafen Risk and Car-
diovascular Health study, with a large cohort of patients (~3800) with a data-
base of clinical and metabolic parameters, we have selected candidate gene
and their variants associated with CVDs. To determine the functional impact
of these variants, we produce mutant mice, reproducing targeted genomic
changes found for each gene. These mice are fed atherogenic diet at 11-
12 weeks of age and studied to determine metabolic and physiological conse-
quences of these variants. Workflow focuses on arterial blood pressure by
NIBP, progression of atherosclerotic plaques size and composition and ste-
atosis formation by echography of the main arteries branching (carotid, aorta,
renal arteries…). We measure also body composition and glucose tolerance by
qNMR and OGTT respectively. Blood is collected to assess plasmatic cho-
lesterol levels (HDL, LDL, TG) and organs are weighted (heart, kidney,
spleen…) and used for RNA seq analysis. The identification of genetic factors
responsible for phenotypic traits associated with CVDs and characterization of
their impact on physiological and molecular level will allow us not only to
better understand the genetic mechanisms promoting CVDs, but also to iden-
tify markers for better prevention and treatment of CVDs.
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Background: Antithrombotic therapies reduce the risk of recurrent
ischemic events in acute STEMI, but are responsible for an increase in
bleeding events.
Aim: To describe the incidence and identify the predictive factors of
bleeding events in patients revascularized within the first 12 hours of STEMI
at Grenoble University Hospital.
Methods: We analyzed data from 276 consecutive pts prospectively
included in the RESURCOR registry and determined the incidence, severity
(TIMI, and BARC bleeding scores), sites, and associated complications of
bleeding events. Crusade score, clinical history and therapies administered
before coronary angiography (CA) were collected.
Results: All 276 pts underwent CA, 74 (27%) after thrombolysis and 202
(73%) for primary-PCI (radial route = 82%). One or more bleeding event
occurred in 27 pts (9.8%): TIMI major n=13 (4.7%) and minor n=14 (5.1%).
Patients with bleeding complications were more often female (p=0.012), were
older (p=0.016), had lower body weight (p=0.023), presented more often with
cardiogenic shock (p=0.001), required more often circulatory support
(p<0.00001), and had higher CRUSADE score (32.4+15.7 vs. 25.2+13.7
p=0.016) than pts without bleeding. Mortality was 30.8, and 4.0% in pts with
major, and no bleeding respectively (p<0.0001). Independent predictors of
bleeding events were an older age, female gender, low body weight and
presence of heart failure on admission. In emergency situation, bleeding risk
evaluation by the clinician modified the management of STEMI, with less
GPIIbIIa inhibitors (p=0.004) and thrombolytic agents (p=0.04) prescribed in
pts with a high risk of bleeding.
Conclusion: The incidence of bleedings in STEMI remains stable despite
more powerful antithrombotic agents, probably in relation with radial access
and awareness of the bleeding risk by the clinician. Our study also confirms
that bleeding events are strongly associated with in-hospital mortality.
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During platelet activation, class I phosphoinositide 3-kinase β (PI3Kβ)
generate the lipid second messengers PtdIns(3,4,5)P3 which is an important
players in the organization of the platelet signaling machinery downstream of
activator receptors and integrins. Since PI3Kβ inhibition prevents occlusive
thrombus formation with a limited increase in bleeding risk and acceptable
safety in humans, this kinase has been proposed as a potential antithrombotic
drug target. However, the role of platelet PI3Kβ in integrated in vivo or ex
vivo models of thrombosis upon high shear rate condition found in stenosed
arteries remains incompletely documented.
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Using pharmacological and genetic approaches we investigated the role of
platelet PI3Kβ and downstream effectors in thrombus formation and stabiliza-
tion specifically under pathological shear rates conditions ex vivo in a micro-
fluidic blood flow system, and in vivo following deep injury of the arterial
vascular wall. We demonstrated a critical role of PI3Kβ in thrombus stability
both ex vivo and in vivo under high shear rate. Absence or inhibition of
PI3Kβ within the growing platelet thrombus affect the activation of the serine/
threonine kinase Akt and impairs the inhibition of its downstream effector
GSK3. Interestingly, pharmacological inhibition of GSK3 restores thrombus
stability. Similar results were obtained with human blood treated with
AZD6482, a selective PI3Kβ inhibitor highlighting the role of the kinase
activity of p110β in this context. We also show that PI3Kβ is not involved in
thrombus stability.
Overall, our data show that platelet PI3Kβ is a key regulator of
thrombus stability at pathological shear rate and suggest that emboli shed-
ding may be a consequence of PI3Kβ targeting in antithrombotic therapy.
Moreover, absence of PI3Kβ cannot be compensated by PI3Kβ but by GSK3
inhibition.
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